United Therapeutics

Thesis

United Therapeutics (NASDAQ: UTHR) has a ~$13B+ market cap and is profitable from its pulmonary hypertension drug franchise. Its Revivicor subsidiary produces 10-gene-edited pigs. FDA cleared the IND for its UKidney EXPAND clinical trial (February 2025), with the first transplant performed November 2025. Building a $100M organ production facility. Seven organ programs total. Described as 'the best risk-adjusted frontier play in the entire report'. And the logic is compelling. UTHR is a profitable company with existing revenue where the xenotransplantation division represents pure optionality. If pig organs work at scale, the addressable market (100,000+ Americans on waitlists, 17 dying daily) could dwarf the current pulmonary hypertension franchise. If they don't work, you still own a profitable drug company. The $100M organ production facility under construction signals serious commitment to scale. Seven organ programs (not just kidneys) multiply the optionality. The FDA IND clearance for UKidney EXPAND puts this in formal clinical trials. This is the rare frontier opportunity where downside is protected by existing profitability and upside is potentially transformative. At $13B market cap, a successful xeno program could easily double or triple the company's value.

Catalysts

• +FDA IND cleared for UKidney EXPAND trial, first transplant Nov 2025
• +$100M organ production facility under construction. Scaling commitment
• +Seven organ programs provide diversified optionality beyond kidneys

Risks

• -Organ rejection at scale could invalidate the entire xenotransplantation thesis
• -Regulatory approval timeline extends years beyond initial trials
• -Ethical and religious objections to pig organ transplants could limit adoption

Common questions